JP2008515959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008515959A5 JP2008515959A5 JP2007536244A JP2007536244A JP2008515959A5 JP 2008515959 A5 JP2008515959 A5 JP 2008515959A5 JP 2007536244 A JP2007536244 A JP 2007536244A JP 2007536244 A JP2007536244 A JP 2007536244A JP 2008515959 A5 JP2008515959 A5 JP 2008515959A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- amino
- phenyl
- yloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 194
- -1 cyano, hydroxy, mercapto, amino Chemical group 0.000 claims 135
- 229910052757 nitrogen Inorganic materials 0.000 claims 62
- 229910052739 hydrogen Inorganic materials 0.000 claims 28
- 239000001257 hydrogen Substances 0.000 claims 28
- 125000000623 heterocyclic group Chemical group 0.000 claims 26
- 229910052760 oxygen Inorganic materials 0.000 claims 25
- 125000003118 aryl group Chemical group 0.000 claims 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 22
- 125000001424 substituent group Chemical group 0.000 claims 22
- 125000005236 alkanoylamino group Chemical group 0.000 claims 20
- 125000001072 heteroaryl group Chemical group 0.000 claims 20
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 150000003246 quinazolines Chemical class 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 125000003282 alkyl amino group Chemical group 0.000 claims 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 15
- 125000003342 alkenyl group Chemical group 0.000 claims 14
- 125000000304 alkynyl group Chemical group 0.000 claims 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 13
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- 125000001589 carboacyl group Chemical group 0.000 claims 12
- 125000001153 fluoro group Chemical group F* 0.000 claims 11
- 239000000651 prodrug Substances 0.000 claims 10
- 229940002612 prodrug Drugs 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 125000005281 alkyl ureido group Chemical group 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 9
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 239000001301 oxygen Substances 0.000 claims 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 239000011593 sulfur Chemical group 0.000 claims 8
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 7
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 7
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 7
- 125000004414 alkyl thio group Chemical group 0.000 claims 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 7
- 125000002950 monocyclic group Chemical group 0.000 claims 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000002619 bicyclic group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004423 acyloxy group Chemical group 0.000 claims 5
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000003302 alkenyloxy group Chemical group 0.000 claims 4
- 125000005133 alkynyloxy group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 3
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- OEZUXIBNCYTQAV-UHFFFAOYSA-N 2-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-n-[5-(dimethylamino)pyridin-2-yl]acetamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=C1)=CC=C1CC(=O)NC1=CC=C(N(C)C)C=N1 OEZUXIBNCYTQAV-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000003502 anti-nociceptive effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- WSWMGHRLUYADNA-UHFFFAOYSA-N 7-nitro-1,2,3,4-tetrahydroquinoline Chemical compound C1CCNC2=CC([N+](=O)[O-])=CC=C21 WSWMGHRLUYADNA-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04292417 | 2004-10-12 | ||
| PCT/GB2005/003846 WO2006040520A1 (en) | 2004-10-12 | 2005-10-07 | Quinazoline derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008515959A JP2008515959A (ja) | 2008-05-15 |
| JP2008515959A5 true JP2008515959A5 (cg-RX-API-DMAC10.html) | 2008-10-16 |
| JP4237242B2 JP4237242B2 (ja) | 2009-03-11 |
Family
ID=35455960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536244A Expired - Fee Related JP4237242B2 (ja) | 2004-10-12 | 2005-10-07 | キナゾリン誘導体 |
Country Status (18)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US20070123539A1 (en) * | 2005-10-20 | 2007-05-31 | University Of South Florida | Treatment of Restenosis and Stenosis with Dasatinib |
| PT2404919E (pt) | 2005-11-08 | 2013-10-22 | Vertex Pharma | Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| UY30183A1 (es) * | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2007113565A1 (en) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives as anti-cancer agents |
| JP5159630B2 (ja) | 2006-09-13 | 2013-03-06 | 協和発酵キリン株式会社 | 縮環複素環誘導体 |
| EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| AR064517A1 (es) | 2006-12-22 | 2009-04-08 | Avexa Ltd | Pirimidinionas biciclicas y sus usos |
| EP2164840A2 (en) | 2007-05-09 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| HUE049642T2 (hu) | 2007-12-07 | 2020-09-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái |
| CA2989620C (en) | 2007-12-07 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| FR2926554B1 (fr) | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
| CA2716109C (en) | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| GB0901834D0 (en) | 2009-02-04 | 2009-03-11 | Syngenta Ltd | Novel herbicides |
| GB0901835D0 (en) | 2009-02-04 | 2009-03-11 | Syngenta Ltd | Novel herbicides |
| EP2484678B1 (en) | 2009-09-28 | 2015-01-21 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors |
| ES2900353T3 (es) | 2010-04-07 | 2022-03-16 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas |
| CN102408426B (zh) * | 2011-09-14 | 2013-07-10 | 湖南有色凯铂生物药业有限公司 | 取代的芳香脲类化合物及其作为抗癌药物的应用 |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| WO2014032755A2 (en) * | 2012-08-29 | 2014-03-06 | Merck Patent Gmbh | Ddr2 inhibitors for the treatment of osteoarthritis |
| CA2930199C (en) | 2013-11-12 | 2022-10-25 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
| HUE055423T2 (hu) | 2014-11-18 | 2021-11-29 | Vertex Pharma | Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére |
| AU2018259078B2 (en) | 2017-04-27 | 2021-10-07 | Astrazeneca Ab | C5-anilinoquinazoline compounds and their use in treating cancer |
| US11053223B2 (en) | 2017-04-27 | 2021-07-06 | Astrazeneca Ab | Phenoxyquinazoline compounds and their use in treating cancer |
| WO2019046668A1 (en) * | 2017-08-31 | 2019-03-07 | Kezar Life Sciences | AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN |
| CN113061113A (zh) * | 2021-04-07 | 2021-07-02 | 中北大学 | 一种4-硝基咪唑的制备方法 |
| CN115594602B (zh) * | 2021-07-09 | 2024-01-30 | 南京大学 | 一种可见光诱导的合成芳香胺的方法 |
| CN118510502A (zh) * | 2021-11-05 | 2024-08-16 | 乔治穆内公司 | Akt3调节剂 |
| WO2024112854A1 (en) | 2022-11-22 | 2024-05-30 | Odyssey Therapeutics, Inc. | Inhibitors of ripk2 and medical uses thereof |
| EP4734982A2 (en) * | 2023-06-29 | 2026-05-06 | Ohio State Innovation Foundation | Mitochondrial complex i inhibitors with reduced phosphodiesterase inhibition |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| DE69222637T2 (de) | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (cg-RX-API-DMAC10.html) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| US6017919A (en) | 1996-02-06 | 2000-01-25 | Japan Tobacco Inc. | Compounds and pharmaceutical use thereof |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| WO1999047529A1 (en) | 1998-03-18 | 1999-09-23 | Ariad Pharmaceuticals, Inc. | Heterocyclic signal transduction inhibitors, compositions containing them |
| CN1158266C (zh) | 1998-10-01 | 2004-07-21 | 阿斯特拉曾尼卡有限公司 | 化合物 |
| ES2241324T3 (es) * | 1998-10-08 | 2005-10-16 | Astrazeneca Ab | Derivados de quinazolina. |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| HK1046688A1 (zh) * | 1999-09-21 | 2003-01-24 | Astrazeneca Ab | 喹唑啉化合物和含有喹唑啉化合物的藥物組合物 |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| EE200200119A (et) * | 1999-09-21 | 2003-04-15 | Astrazeneca Ab | Kinasoliini derivaadid ja nende kasutamine ravimitena |
| GB9922173D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| US6531291B1 (en) | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
| EP1294709A2 (en) | 2000-01-28 | 2003-03-26 | AstraZeneca AB | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| CA2413702A1 (en) * | 2000-06-28 | 2002-01-03 | Teva Pharmaceuticals Industries Ltd. | Carvedilol |
| BR0111754A (pt) * | 2000-06-28 | 2003-04-29 | Astrazeneca Ab | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica |
| AU2001286909B2 (en) | 2000-09-01 | 2006-02-09 | Bayer Cropscience Ag | Disubstituted benzenes as insecticides |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| GB0126433D0 (en) | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| RU2004116911A (ru) | 2001-11-03 | 2005-11-10 | Астразенека Аб (Se) | Производные хиназолина в качестве противоопухолевых средств |
| ATE446093T1 (de) | 2001-12-24 | 2009-11-15 | Astrazeneca Ab | Substituierte chinazolin-derivate als aurora- kinase inhibitoren |
| EP2292615A1 (en) | 2002-02-01 | 2011-03-09 | AstraZeneca AB | Quinazoline compounds |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| WO2004007472A1 (ja) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ｃｃｒ４アンタゴニストおよびその医薬用途 |
| WO2004024705A1 (ja) | 2002-09-10 | 2004-03-25 | Takeda Pharmaceutical Company Limited | ５員複素環化合物 |
| ATE412657T1 (de) | 2002-12-24 | 2008-11-15 | Astrazeneca Ab | Therapeutische quinazolin-derivate |
| WO2004058752A1 (en) | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | Quinazoline compounds |
| UA83814C2 (ru) * | 2002-12-24 | 2008-08-26 | Астразенека Аб | Производные фосфонооксихиназолина и их фармацевтическое применение |
| RU2005135337A (ru) | 2003-04-16 | 2006-06-10 | Астразенека Аб (Se) | Производные хиназолина для лечения злокачественного новообразования |
| EP1617840A4 (en) | 2003-05-01 | 2008-08-20 | Bristol Myers Squibb Co | PYRAZOLE AMID COMPOUNDS AS KINASE INHIBITORS |
| DE602004015108D1 (de) | 2003-06-02 | 2008-08-28 | Astrazeneca Ab | (3-((chinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs |
| TW200505452A (en) | 2003-06-17 | 2005-02-16 | Astrazeneca Ab | Chemical compounds |
| GB0318422D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| WO2005021554A1 (en) | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents |
| EP1661889A4 (en) | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| JP2008515960A (ja) | 2004-10-12 | 2008-05-15 | アストラゼネカ アクチボラグ | キノリン誘導体 |
| US20090036474A1 (en) | 2004-10-12 | 2009-02-05 | Patrick Ple | Quinazoline derivatives for use against cancer |
| AU2006204724A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
| GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| JP2009528335A (ja) | 2006-03-02 | 2009-08-06 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| US20090076075A1 (en) | 2006-03-02 | 2009-03-19 | Frederic Henri Jung | Quinoline derivatives |
| EP1994028A1 (en) | 2006-03-02 | 2008-11-26 | AstraZeneca AB | Quinoline derivatives for treating cancer |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2007113565A1 (en) | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives as anti-cancer agents |
| WO2007113548A1 (en) | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives |
-
2005
- 2005-10-07 MX MX2007004403A patent/MX2007004403A/es active IP Right Grant
- 2005-10-07 NZ NZ554017A patent/NZ554017A/en not_active IP Right Cessation
- 2005-10-07 EP EP05789135A patent/EP1802591B1/en not_active Expired - Lifetime
- 2005-10-07 CN CN2005800420488A patent/CN101072758B/zh not_active Expired - Fee Related
- 2005-10-07 KR KR1020077010679A patent/KR20070084172A/ko not_active Ceased
- 2005-10-07 AU AU2005293336A patent/AU2005293336B2/en not_active Ceased
- 2005-10-07 AT AT05789135T patent/ATE540935T1/de active
- 2005-10-07 WO PCT/GB2005/003846 patent/WO2006040520A1/en not_active Ceased
- 2005-10-07 US US11/665,125 patent/US8153643B2/en not_active Expired - Fee Related
- 2005-10-07 JP JP2007536244A patent/JP4237242B2/ja not_active Expired - Fee Related
- 2005-10-07 BR BRPI0516093-6A patent/BRPI0516093A/pt active Search and Examination
- 2005-10-07 ES ES05789135T patent/ES2378772T3/es not_active Expired - Lifetime
- 2005-10-07 CA CA2581516A patent/CA2581516C/en not_active Expired - Fee Related
- 2005-10-12 TW TW094135541A patent/TW200630347A/zh unknown
- 2005-10-12 AR ARP050104277A patent/AR051215A1/es not_active Application Discontinuation
-
2007
- 2007-03-21 IL IL182094A patent/IL182094A0/en unknown
- 2007-03-30 NO NO20071703A patent/NO20071703L/no not_active Application Discontinuation
- 2007-04-05 ZA ZA200702877A patent/ZA200702877B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008138993A (ru) | Производные хинолина | |
| CN101072758B (zh) | 喹唑啉衍生物 | |
| RU2219171C2 (ru) | Производные амида, способ их получения и фармацевтическая композиция на их основе | |
| KR101877187B1 (ko) | 치환된 다이하이드로이소퀴놀린온 화합물 | |
| US9718787B2 (en) | Poly (ADP-ribose) polymerase inhibitor | |
| CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
| JP2017519021A5 (cg-RX-API-DMAC10.html) | ||
| RU2770824C2 (ru) | Противоопухолевый агент | |
| JP2002528537A (ja) | ２−アミノ−チアゾール誘導体類、それらの製造方法および抗癌剤としてのそれらの使用 | |
| CA2806610A1 (en) | Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k | |
| CA2519301A1 (en) | Oxime derivatives and their use as pharmaceutically active agents | |
| CN108366979A (zh) | 与泛素化－蛋白酶体系统有关的化合物及医药组合物 | |
| JP2008515961A (ja) | 癌に対する使用のためのキナゾリン誘導体 | |
| KR20210072787A (ko) | 저분자 메닌 억제제 | |
| EP3802525A1 (en) | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof | |
| CN106892907A (zh) | 含酰腙结构的喹唑啉类化合物及其应用 | |
| WO2015125786A1 (ja) | アミノピラゾロン誘導体 | |
| CN101423513B (zh) | 胺基嘧啶衍生物、及其制法和药物组合物与用途 | |
| US20120165351A1 (en) | Quinazoline derivatives | |
| WO2021141538A1 (en) | Combination therapy | |
| WO2024099435A1 (zh) | Tead抑制剂 | |
| CN101437810A (zh) | 喹唑啉衍生物 | |
| HK1107339B (en) | Quinazoline derivatives | |
| CN101437811A (zh) | 喹啉衍生物 |